Full-Time
Confirmed live in the last 24 hours
Develops advanced biotech and high-tech products
Senior, Expert
No H1B Sponsorship
North Carolina, USA
Candidates must be US citizens or US permanent residents.
US Citizenship Required
You match the following Science's candidate preferences
Employers are more likely to interview you if you match these preferences:
Science.xyz develops specialized products and services in the biotech and high-tech sectors, focusing on areas like synthetic biology, stem cell research, microfabrication, and semiconductor devices. Their products work by utilizing advanced scientific research and technology to provide solutions tailored to the needs of academic institutions, research labs, and biotech companies. What sets Science.xyz apart from its competitors is its strong emphasis on collaboration and partnerships within the scientific community, as well as its team of skilled professionals who drive their research and development efforts. The company's goal is to create valuable scientific solutions that contribute to advancements in technology and improve outcomes in various scientific fields.
Company Size
201-500
Company Stage
Seed
Total Funding
$25.3M
Headquarters
Alameda, California
Founded
2021
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Flexible Vacation
Paid Parental Leave
Paid Sick Leave
401(k) Retirement Plan
Dependent Care Flexible Spending Account
Flexible Spending Account
At Science, Science Corp. is developing a biohybrid probe technology using highly engineered, stem cell-derived neurons embedded in vitro in electronics and engrafted into the brain, forming new biological connections.
Trinity Capital will build move-in ready lab space on a full floor of the recently opened Roxboro office tower in Durham to boost leasing activity.
Today Science Corp. is releasing two separate but related technologies: the SciFi wireless headstage and the Synapse protocol which is spoken by all of Science's neural interface devices.
Science Corp. acquired the technology from Paris-based Pixium Vision SA in April.
Science Corporation welcomes Tricia Gugler as Chief Financial Officer, Alex Feerst as Chief Legal Officer, and joe Mornin as General Counsel.
The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.The reader should not assume that the information is accurate and complete.
ALAMEDA, CALIFORNIE--(BUSINESS WIRE)--Science Corporation (« Science »), leader de la technologie d'interface neuronale directe (« IND ») et développeur de Science Eye, a fait l’acquisition des droits de PI et des actifs associés pour l’implant rétinien PRIMA, développé par Pixium Vision SA (« Pixium »), société de technologie IND bioélectronique. La transaction a été annoncée dans un article de blog scientifique par le PDG et cofondateur Max Hodak, qui a déclaré : « L'implant rétinien PRIMA, développé par Pixium et basé sur des recherches menées à l'université de Stanford, est très prometteur. Les premiers résultats des essais cliniques sont impressionnants. Ce dispositif, ainsi que le travail effectué sur Science Eye par Science, représentent désormais deux grandes opportunités de développement de la technologie IND visant une potentielle restauration de la vision chez des patients souffrant d’une perte de vision sévère. Nous nous engageons à apporter aux patients une restauration cliniquement significative de leur vision le plus rapidement possible. »
ALAMEDA, Calif.--(BUSINESS WIRE)--Science Corporation (“Science”), a leader in brain-computer interface (“BCI”) technology and the developer of the Science Eye, has acquired the IP and related assets for the PRIMA retinal implant, developed by Pixium Vision SA (“Pixium”) of France, a bioelectronics BCI technology company. The transaction was announced in a Science blog post by CEO and co-founder Max Hodak, who said: “The PRIMA retinal implant, developed by Pixium and based on research done at Stanford University, shows great promise. The early clinical trial results we’ve seen are impressive. Together with the work being done at Science on the Science Eye, we now have two great opportunities to develop BCI technology for the potential restoration of vision in certain patients with severe vision loss. We are committed to bringing meaningful restoration of vision to patients as quickly as possible.”. Lloyd Diamond, outgoing CEO of Pixium, added: “I am thrilled to see our projects at Pixium going to Science, and in the hands of the outstanding scientists and engineers who are part of their team
Companies the firm has backed include Modern Meadow, Excision Bio, Locus Biosciences, Eko, Aether, and Freenome among others.